- Home
-
Press releases
-
Media academy
- Lung Cancer
- Breast Cancer
- Ovarian Cancer
- Head & Neck Cancer
- Targeted Therapy
Boehringer Ingelheim
A Phase I/II open-label trial of continuous once-daily oral treatment with afatinib* (compound code BIBW 2992) – Phase I trial in advanced non-small cell lung cancer (NSCLC) patients & Phase II trial in NSCLC patients failing erlotinib or gefitinib.
*Afatinib (compound code BIBW 2992) is an investigational compound. Its efficacy and safety has not been fully established.
Source for healthcare professionals: www.inoncology.com
* Nintedanib (BIBF 1120), afatinib (BIBW 2992) and volasertib (BI 6727) are investigational compounds. Their safety and efficacy have not yet been fully established.
